Vanda Pharmaceuticals' VEC-162 Demonstrates Positive Results In A Phase III Transient Insomnia Clinical Trial

... Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced positive top-line results from the company's Phase III clinical trial evaluating VEC-162, a balanced melatonin receptor agonist, in transient insomnia. [click link for full article] ...